Your browser doesn't support javascript.
loading
A deep-learning framework to predict cancer treatment response from histopathology images through imputed transcriptomics.
Hoang, Danh-Tai; Dinstag, Gal; Shulman, Eldad D; Hermida, Leandro C; Ben-Zvi, Doreen S; Elis, Efrat; Caley, Katherine; Sammut, Stephen-John; Sinha, Sanju; Sinha, Neelam; Dampier, Christopher H; Stossel, Chani; Patil, Tejas; Rajan, Arun; Lassoued, Wiem; Strauss, Julius; Bailey, Shania; Allen, Clint; Redman, Jason; Beker, Tuvik; Jiang, Peng; Golan, Talia; Wilkinson, Scott; Sowalsky, Adam G; Pine, Sharon R; Caldas, Carlos; Gulley, James L; Aldape, Kenneth; Aharonov, Ranit; Stone, Eric A; Ruppin, Eytan.
Affiliation
  • Hoang DT; Biological Data Science Institute, College of Science, Australian National University, Canberra, Australian Capital Territory, Australia. danhtai.hoang@anu.edu.au.
  • Dinstag G; Pangea Biomed Ltd., Tel Aviv, Israel.
  • Shulman ED; Cancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Hermida LC; Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.
  • Ben-Zvi DS; Tumor Microenvironment Center, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
  • Elis E; Pangea Biomed Ltd., Tel Aviv, Israel.
  • Caley K; Pangea Biomed Ltd., Tel Aviv, Israel.
  • Sammut SJ; Biological Data Science Institute, College of Science, Australian National University, Canberra, Australian Capital Territory, Australia.
  • Sinha S; Breast Cancer Now Toby Robins Research Centre, Institute of Cancer Research, London, UK.
  • Sinha N; The Royal Marsden Hospital NHS Foundation Trust, London, UK.
  • Dampier CH; Cancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Stossel C; Cancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Patil T; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Rajan A; Oncology Institute, Sheba Medical Center at Tel-Hashomer, Tel Aviv University, Tel Aviv, Israel.
  • Lassoued W; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
  • Strauss J; Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Bailey S; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Allen C; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Redman J; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Beker T; Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Jiang P; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Golan T; Pangea Biomed Ltd., Tel Aviv, Israel.
  • Wilkinson S; Cancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Sowalsky AG; Oncology Institute, Sheba Medical Center at Tel-Hashomer, Tel Aviv University, Tel Aviv, Israel.
  • Pine SR; Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Caldas C; Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Gulley JL; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
  • Aldape K; School of Clinical Medicine, University of Cambridge, Cambridge, UK.
  • Aharonov R; Genitourinary Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Stone EA; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Ruppin E; Pangea Biomed Ltd., Tel Aviv, Israel.
Nat Cancer ; 2024 Jul 03.
Article in En | MEDLINE | ID: mdl-38961276
ABSTRACT
Advances in artificial intelligence have paved the way for leveraging hematoxylin and eosin-stained tumor slides for precision oncology. We present ENLIGHT-DeepPT, an indirect two-step approach consisting of (1) DeepPT, a deep-learning framework that predicts genome-wide tumor mRNA expression from slides, and (2) ENLIGHT, which predicts response to targeted and immune therapies from the inferred expression values. We show that DeepPT successfully predicts transcriptomics in all 16 The Cancer Genome Atlas cohorts tested and generalizes well to two independent datasets. ENLIGHT-DeepPT successfully predicts true responders in five independent patient cohorts involving four different treatments spanning six cancer types, with an overall odds ratio of 2.28 and a 39.5% increased response rate among predicted responders versus the baseline rate. Notably, its prediction accuracy, obtained without any training on the treatment data, is comparable to that achieved by directly predicting the response from the images, which requires specific training on the treatment evaluation cohorts.

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Nat Cancer Year: 2024 Document type: Article Affiliation country: Australia

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Nat Cancer Year: 2024 Document type: Article Affiliation country: Australia